Novavax (NVAX) Return on Invested Capital (2025 - 2026)
Novavax's (NVAX) quarterly Return on Invested Capital came in at 0.17% in Q1 2026, down 24.0% year-on-year from 0.23% in Q1 2025, and down 225.49% quarter-over-quarter from 0.14% in Q4 2025.
Novavax (NVAX) Return on Invested Capital (2025 - 2026) Analysis & Trends
Novavax's Return on Invested Capital history runs 2 years deep, the most recent figure standing at 0.17% for Q1 2026.
- On a quarterly basis, Return on Invested Capital fell 24.0% year-over-year to 0.17% in Q1 2026; TTM through Mar 2026 was 0.17%, a 24.0% decrease from a year earlier, with the FY2025 full-year figure at 0.14%, changed N/A from the prior year.
- Return on Invested Capital fell to 0.17% in Q1 2026 per NVAX's latest filing, from 0.14% in the prior quarter.
- Across five years, Return on Invested Capital topped out at 0.14% in Q4 2025 and bottomed at 0.17% in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.00% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.04% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Novavax | 788.01 Mn | -2.33 Mn | 108.82 Mn | -0.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.17% |
| Dec 31, 2025 | 0.14% |
| Sep 30, 2025 | 0.05% |
| Jun 30, 2025 | 0.06% |
| Mar 31, 2025 | 0.07% |